Efluelda TIV susp inj 2025/2026, , Efluelda TIV susp inj 2025/2026 ser pré 0.5 ml

7680698630036 CH-69863 J07BB02

No images available

Details

Product number
-
CPT
-
Packaging group
-
Unit
-

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Professional SmPC
Allemand
27/05/2026
Professional SmPC
Français
27/05/2026
Professional SmPC
Italien
27/05/2026

Detailed composition

Substance Quantity Type Category
haemagglutininum influenzae A (H1N1)
60.0 UG Substance Wirkstoff (Principe actif)
haemagglutininum influenzae A (H3N2)
60.0 UG Substance Wirkstoff (Principe actif)
haemagglutininum influenzae B
60.0 UG Substance Wirkstoff (Principe actif)
natrii chloridum
- Substance HNIDK
dinatrii phosphas
- Substance HNIDK
natrii dihydrogenophosphas anhydricus
- Substance HNIDK
octoxinolum-9
- Substance HNIDK
aqua ad iniectabile
- Substance HNIDK
natrium
1.96 MG Substance HBESI

Reimbursement information

Public price
CHF 40.85
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/01/2026

Authorization holder

Sanofi-Aventis (Suisse) SA

1214 Vernier

Authorization information

Swissmedic authorization number
69863
Drug name
Efluelda TIV, suspension injectable en seringue pré-remplie
Galenic form
SUPAS
ATC Code
J07BB02
Authorization status
Z
Dispensation category
B
First authorization
07/04/2025
Authorization expiration date
06/04/2030
IT number
08.08.
Domain
Human medicine

Packaging details

Description (FR)
EFLUELDA TIV 0.5 mL susp inj 60 µg 1 pce
Description (DE)
EFLUELDA TIV 0.5 mL Inj Susp 60 µg 1 Stk
Market launch
01/01/2026
Narcotic (BTM)
No

Other packaging sizes

EFLUELDA TIV 0.5 mL susp inj 60 µg 1 pce
1 FESP
GTIN: 7680698630050
View
Buy us a coffee Explore the data